Mer­ck KGaA, Mil­li­pore­Sig­ma make in­vest­ments in the US and Chi­na man­u­fac­tur­ing

Mer­ck KGaA an­nounced a pair of man­u­fac­tur­ing ex­pan­sions in the US and Chi­na that aim to in­crease the pro­duc­tion of test­ing ma­te­ri­als and cell cul­tures.

The Ger­man drug­mak­er last week an­nounced that it ex­pects to ex­pand its man­u­fac­tur­ing ca­pac­i­ty for pro­duc­ing high­ly-pu­ri­fied reagents used for qual­i­ty con­trol and test­ing at its site in Nan­tong, Chi­na. It plans to in­vest €70 mil­lion ($78.1 mil­lion) in build­ing a new reagent pro­duc­tion plant there that will cov­er 40,000 square me­ters or about 430,000 square feet. Once com­plet­ed, the fa­cil­i­ty will in­crease its reagent out­put by around sev­er­al thou­sand tons.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.